CD14 and melanoma: Moreover, IFN-α priming may also have a “mobilizing” activity on DC precursors: it was recently been reported that 1–3 MU subcutaneous IFN-α enhances the proportion of circulating CD14+ and CD14 + CD16+ monocytes in both healthy donors and melanoma patients [26].